Diabetes

September 7, 2017

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Rivaroxaban (Trade name: Xarelto), an anti-coagulant and a blood thinner,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 8/September/2017, 12.32 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that […]
September 1, 2017

Molecular therapy for Metabolic diseases: Rivaroxaban (Trade name: Xarelto), an anticoagulant drug, increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, increases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene., 1/September/2017, 11.51 pm

Introduction: What they say A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.” […]
September 1, 2017

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Ruxolitinib, a drug used in the treatment of Myelofibrosis,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 1/September/2017, 11.28 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that […]
August 31, 2017

Molecular therapy for glucose homeostasis and TIIDM: Rivaroxaban (Brand name: Xarelto) increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 1/September/2017, 1.37 am

Introduction: What they say A study from the Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, […]